Abstract
Background
Grey zones, which are defined as tissue with intermediate signal intensity in the area of primary hyperintense tumour extension, can be seen during radiation with or without chemotherapy on the T2-weighted MRI in patients with cervical cancer. The purpose of this study was to systematically measure the tumour volume at the time of diagnosis and the residual tumour volume at the time of brachytherapy without and with consideration of the grey zones and to estimate tumour regression during external beam radiotherapy (EBRT).
Material and methods
T2-weighted MRI datasets of 175 patients with locally advanced cervical cancer (FIGO stage IB–IVA), who underwent combined external beam radiotherapy and brachytherapy with or without concomitant chemotherapy were available for this study. The gross tumour volume at the time of diagnosis (GTVinit) and at the time of first brachytherapy without (GTVres) and with (GTVres+ GZ) consideration of grey zones were measured for each patient. A descriptive statistical analysis was performed and tumour regression rates without (R) and with consideration of grey zones (RGZ) were calculated. Further, the role of prognostic factors on GTVinit, GTVres, GTVres+ GZ and tumour regression rates was investigated.
Results
The median GTVinit, GTVres, GTVres+ GZ in all patients were 44.4 cm3, 8.2 cm3, 20.3 cm3, respectively. The median R was 78.5% and the median RGZ was 50.1%. The histology and FIGO staging showed a significant impact on GTVinit, GTVres and GTVres+ GZ.
Conclusion
Grey zones represent a substantial proportion of the residual tumour volume at the time of brachytherapy. Differentiation of high signal intensity mass and surrounding intermediate signal intensity grey zones may be reasonable.
Zusammenfassung
Hintergrund
Sogenannte Grauzonen können im Verlauf der Radiochemotherapie auf der T2-gewichteten MRT bei Patientinnen mit Zervixkarzinomen als Areal mit intermediärer Signalintensität im Gebiet des initialen hyperintensen Tumors beobachtet werden. Das Ziel dieser Studie war es, das Tumorvolumen zum Zeitpunkt der Diagnose und zum Zeitpunkt der Brachytherapie mit und ohne Berücksichtigung der Grauzonen zu erfassen und die daraus resultierende Tumorregression während der externen Strahlentherapie (EBRT) zu berechnen.
Material und Methode
T2-gewichtete MRT-Datensätze von 175 Patientinnen mit lokal fortgeschrittenem Zervixkarzinom (FIGO-Stadien IB–IVA), die mittels kombinierter EBRT und Brachytherapie mit und ohne konkomittante Chemotherapie behandelt worden waren, waren für diese Studie verfügbar. Für jede Patientin wurden das „Gross Tumor Volume“ (GTV) zum Zeitpunkt der Diagnose (GTVinit) sowie zum Zeitpunkt der Brachytherapie mit (GTVres+ GZ) und ohne Berücksichtigung der Grauzonen (GTVres) erfasst. Eine deskriptive statistische Analyse wurde durchgeführt und die Tumorregression mit (R) und ohne Berücksichtigung der Grauzonen (RGZ) berechnet. Desweiteren wurden der Einfluss prognostischer Faktoren auf GTVinit, GTVres, GTVres+ GZ und Tumorregressionsraten untersucht.
Ergebnisse
Das mediane GTVinit, GTVres und GTVres+ GZ aller Patientinnen betrug jeweils 44,4 cm3, 8,2 cm3 und 20,3 cm3. Die mediane R lag bei 78,5% und die mediane RGZ bei 50,1%. Die Histologie und das FIGO-Stadium hatten einen signifikanten Einfluss auf GTVinit, GTVres und GTVres+ GZ.
Schlussfolgerung
Grauzonen scheinen als Folge der Tumorregression zu entstehen und haben einen wesentlichen Anteil am Tumorvolumen zum Zeitpunkt der Brachytherapie. Eine MR-tomographische Unterscheidung des Resttumors zum Zeitpunkt der Brachytherapie in hohe und intermediäre Signalintensität erscheint sinnvoll.
References
Nagy V, Coza O, Ordeanu C et al (2009) Radiotherapy versus concurrent 5-day cisplatin and radiotherapy in locally advanced cervical carcinoma. Long term results of a phase III randmoized trial. Strahlenther Onkol 185:177–183
Patyánik M, Nemeskéri C, Sinkó D et al (2009) Concomitant radiochemotherapy of cervical cancer: is it justified to reduce the dosage of cisplatin? Strahlenther Onkol 185:582–587
Marnitz S, Stromberger C, Kawgan-Kagan M et al (2010) Helical tomotherapy in cervical cancer patients: simultaneous integrated boost concept: technique and acute toxicity. Strahlenther Onkol 186:572–579
Heinzelmann F, Henke G, von Grafenstein M et al (2012) Adjuvant radiochemotherapy in patients with locally advanced high-risk cervical cancer. Strahlenther Onkol 188:568–575
Gruen A, Musik T, Köhler C et al (2011) Adjuvant chemoradiation after laparoscopically assisted vaginal radical hysterektomy (LARVH) in patients with cervical cancer: oncologic outcome and morbidity. Strahlenther Onkol 187:344–349
Mayr NA, Taoka T, Yuh WTC et al (2002) Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 52:14–22
Nam H, Park W, Huh SJ et al (2007) The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol Oncol 107:320–325
Wang JZ, Mayr NA, Zhang D et al (2010) Sequential magnetic resonance imaging of cervical cancer: the predictive value of absolute tumor volume and regression ratio measured before, during, and after radiation therapy. Cancer 116:5093–5101
Dimopoulos JCA, Schard G, Berger D et al (2006) Systematic evaluation of MRI findings in different stages of treatment of cervical cancer: potential of MRI on delineation of target, pathoanatomic structures, and organs at risk. Int J Radiat Oncol Biol Phys 64:1380–1388
Brocker KA, Alt CD, Eichbaum M et al (2011) Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 1. Strahlenther Onkol 187:611–618
Alt CD, Brocker KA, Eichbaum M et al (2011) Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 2. Strahlenther Onkol 187:705–714
Mayr NA, Tali ET, Yuh WT et al (1993) Cervical cancer: application of MR imaging in radiation therapy. Radiology 189:601–608
Flueckiger F, Ebner F, Poschauko H et al (1992) Cervical cancer: serial MR imaging before and after primary radiation therapy–a 2-year follow-up study. Radiology 184:89–93
Sironi S, Belloni C, Taccagni G et al (1991) Invasive cervical carcinoma: MR imaging after preoperative chemotherapy. Radiology 180:719–722
Haie-Meder C, Pötter R, Van Limbergen E et al (2005) Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74:235–245
Pötter R, Dimopoulos J, Georg P et al (2007) Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 83:148–155
Pötter R, Georg P, Dimopulos J et al (2011) Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100:116–123
Vincens E, Balleyguier C, Rey A et al (2008) Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy. Cancer 113:2158–2164
Allen SD, Padhani AR, Dzik-Jurasz AS, Glynne-Jones R (2007) Rectal carcinoma: MRI with histologic correlation before and after chemoradiation therapy. AJR Am J Roentgenol 188:442–451
Dresen RC, Beets GL, Rutten, HJT et al (2009) Locally advanced rectal cancer: MR Imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy Part I. Are we able to predict tumor confined to the rectal wall? Radiology 252:71–80
Chargari C, Magné N, Dumas I et al (2009) Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Rad Oncol Biol Phys 74:133–139
Toita T, Kakinohana Y, Shinzato S et al (1999) Tumor diameter/volume and pelvic node status assessed by magnetic resonance imaging (MRI) for uterine cervical cancer treated with irradiation. Int J Radiat Oncol Biol Phys 43:777–782
Hatano K, Sekiya Y, Araki H et al (1999) Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 45:639–644
Kirisits C, Pötter R, Lang S et al (2005) Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 262:901–911
Ohara K, Oki A, Tanaka YO et al (2006) Early determination of uterine cervical squamous cell carcinoma radioresponse identifies high- and low-response tumors. Int J Radiat Oncol Biol Phys 64:1179–1182
Lim K, Chan P, Dinniwell R et al (2008) Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: radiobiologic modeling and correlation with tumor hypoxia. Int J Radiat Oncol Biol Phys 70:126–133
Dimopoulos JCA, Schirl G, Baldinger A et al (2009) MRI assessment of cervical cancer for adaptive radiotherapy. Strahlenther Onkol 185:282–287
Tanderup K, Nielsen SK, Nyvang GB et al (2010) From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organ at risk in brachytherapy of cervical cancer. Radiother Oncol 94(2):173–180
Haie-Meder C, Chargari C, Rey A et al (2010) MRI-based low dose-rate brachytherapy experience in locally advanced cervical cancer patients initially treated by concomitant chemoradiotherapy. Radiother Oncol 96:161–165
Jamema SV, Kirisits C, Mahanshetty U et al (2010) Comparison of DVH parameters and patterns of standard loading, manual and inverse optimization for intracavitary brachytherapy on a subset of tandem/ovoid cases. Radiother Oncol 97:501–506
Mayr NA, Yuh WTC, Taoka T et al (2006) Serial therapy-induced changes in tumor shape in cervical cancer and their impact on assessing tumor volume and treatment response. AJR Am J Roentgenol 187:65–72
Barillot I, Horiot JC, Pigneux J et al (1997) Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors. Int J Radiat Oncol Biol Phys 38:969–978
Hong JH, Tsai CS, Wang CC et al (2000) Comparison of clinical behaviors and responses to radiation between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas of the cervix. Chang Gung Med J 23:396–404
Dimopoulos JCA, Petrow P, tanderup K et al (2012) Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiother Oncol 103:113–122
Zahra MA, Tan LT, Priest AN et al (2009) Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer. Int J Radiat Oncol Biol Phys 74:766–773
Mayr NA, Wang JZ, Zhang D et al (2010) Longitudinal changes in tumor perfusion pattern during the radiation therapy course and its clinical impact in cervical cancer. Int J Radiat Oncol Biol Phys 77:502–508
Mayr NA, Huang Z, Wang JZ et al (2012) Characterizing tumor heterogeneity with functional imaging and quantifying high-risk tumor volume for early prediction of treatment outcome: Cervical cancer as a model. Int J Radiat Oncol Biol Phys 83:972–979
Acknowledgement
This study was granted by the Medical Scientific Fund of the Mayor of the City of Vienna: Project No. 07063.
Conflict of interest
On behalf of all authors, the corresponding author states the following: the Department of Radiotherapy at the Medical University of Vienna receives/received financial and/or equipment support for research and educational purposes from Nucletron B.V., Varian Medical Systems, Inc., and Isodose Control B.V.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schmid, M., Mansmann, B., Federico, M. et al. Residual tumour volumes and grey zones after external beam radiotherapy (with or without chemotherapy) in cervical cancer patients. Strahlenther Onkol 189, 238–245 (2013). https://doi.org/10.1007/s00066-012-0260-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-012-0260-7
Keywords
- Uterine cervical neoplasms
- Magnetic resonance imaging
- Remission induction
- Residual neoplasms
- Image-guided adaptive brachytherapy